Tryptophan catabolic process

Across TCGA cell cohorts, RNA activity of the Tryptophan catabolic process pathway is significantly associated with the drug response of multiple features, with the BLOOD_Lymphoma cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are Alisertib, YK-4-279, and Pevonedistat, each associated with the pathway in up to 1 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, Alisertib grouped by Tryptophan catabolic process-low versus -high activity in BLOOD_Lymphoma.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Lymphoma	Alisertib →	-2.215	-2.237	.001	.010	3	1
BLOOD_Lymphoma	YK-4-279 →	-0.740	-2.125	.030	.013	2	1
BLOOD_Lymphoma	Pevonedistat →	-0.735	-2.237	.010	.010	2	1
BLOOD_Lymphoma	Teniposide →	-1.179	-2.237	.036	.010	2	1
BLOOD_Lymphoma	Elephantin →	-0.304	-2.110	.029	.013	2	1
BLOOD_Lymphoma	GSK343 →	-1.034	-2.222	.033	.010	2	1

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Alisertib by Tryptophan catabolic process activity — BLOOD_Lymphoma

Explore this box plot interactively →